Diagnostic test manufacturers can now use human plasma samples to evaluate the accuracy of their tests to detect Zika virus infection.
The FDA has assembled a panel of samples from anonymous patients with Zika, West Nile, or dengue virus infection to help diagnostics manufacturers determine whether their tests can distinguish Zika from the other, similar pathogens—all flaviviruses. “This is part of our effort to ultimately bring these tests through the FDA’s formal review process to better ensure their reliability and to enable broader access to Zika diagnostic testing,” FDA Commissioner Scott Gottlieb, MD, said in a statement.
Voelker R. New Tool to Aid Zika Diagnostics. JAMA. 2017;318(13):1214. doi:10.1001/jama.2017.13881
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.